Tahzib Nayyirih G, Nuijts Rudy M, Wu Wendy Y, Budo Camille J
Department of Ophthalmology, Academic Hospital Maastricht, Maastricht, The Netherlands.
Ophthalmology. 2007 Jun;114(6):1133-42. doi: 10.1016/j.ophtha.2006.09.029. Epub 2007 Feb 1.
To determine the long-term performance of the Artisan phakic intraocular lens (PIOL) for the correction of myopia.
Long-term (10 years) retrospective follow-up study.
Eighty-nine eyes of 49 patients who underwent Artisan PIOL implantation for the correction of myopia.
Comparisons were made between preoperative clinical data and the clinical data at 1, 6, and 10 years after surgery.
Refractive stability, refractive predictability, safety, efficacy, best-corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), intraocular pressure, intraoperative problems, corneal endothelial cell density, corneal endothelial cell loss, and glare levels were evaluated.
The mean spherical equivalent (SE) after 10 years was -0.70+/-1.00 diopters (D; range, -4.00 to 2.00 D), with no significant change in mean SE between 1, 6, and 10 years. At 10 years, 68.8% of all eyes were within 1.0 D of the intended correction. At 10 years, 31.2% (n = 24) gained 1 or more Snellen lines of BCVA and 2.6% (n = 2) lost more than 2 Snellen lines of BCVA; 93.3% reached a BCVA of 20/40 or better, and 82.0% reached a UCVA of 20/40 or better. The mean intraocular pressure remained stable and was 15.5+/-3.5 mmHg (range, 7-25 mmHg) at 10 years. The mean endothelial cell loss was -8.86+/-16.01% (range, -51.69% to 34.43%) at 10 years.
Long-term results demonstrate that the implantation of an Artisan PIOL for the correction of moderate to high myopia is a stable, predictable, and safe method when strict inclusion criteria for surgery are applied. There was no significant loss of corneal endothelial cells and no reports of long-term glare.
确定Artisan有晶状体眼人工晶状体(PIOL)矫正近视的长期效果。
长期(10年)回顾性随访研究。
49例接受Artisan PIOL植入术矫正近视的患者的89只眼。
比较术前临床数据与术后1年、6年和10年的临床数据。
评估屈光稳定性、屈光可预测性、安全性、有效性、最佳矫正视力(BCVA)、未矫正视力(UCVA)、眼压、术中问题、角膜内皮细胞密度、角膜内皮细胞丢失和眩光水平。
10年后平均球镜等效度(SE)为-0.70±1.00屈光度(D;范围,-4.00至2.00 D),1年、6年和10年之间平均SE无显著变化。10年后,所有眼的68.8%在预期矫正的1.0 D范围内。10年后,31.2%(n = 24)的最佳矫正视力提高了1条或更多Snellen行,2.6%(n = 2)的最佳矫正视力下降超过2条Snellen行;93.3%的最佳矫正视力达到20/40或更好,82.0%的未矫正视力达到20/40或更好。平均眼压保持稳定,10年时为15.5±3.5 mmHg(范围,7 - 25 mmHg)。10年时平均内皮细胞丢失为-8.86±16.01%(范围,-51.69%至34.43%)。
长期结果表明,当应用严格的手术纳入标准时,植入Artisan PIOL矫正中高度近视是一种稳定、可预测且安全的方法。角膜内皮细胞无显著丢失,也无长期眩光的报告。